Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 259

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Systematic review and meta‐analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma

Samson, David J., Seidenfeld, Jerome, Schmitt, Brian, Hasselblad, Vic, Albertsen, Peter C., Bennett, Charles L., Wilt, Timothy J., Aronson, Naomi · 2002 · Cancer

Abstract

BACKGROUND: The current systematic review and meta‐analysis compared monotherapy and combined androgen blockade in the treatment of men with advanced prostate carcinoma. Outcomes of interest included overall, cancer specific, and progression‐free survival; time to treatment failure; adverse events; and quality of life. METHODS: The literature search identified randomized trials comparing monotherapy (orchiectomy and luteinizing hormone‐releasing hormone [LHRH] agonists) with combination therapy using orchiectomy or a LHRH agonist plus a nonsteroidal or steroidal antiandrogen. Dual independent review occurred. The meta‐analysis used a random effects model. RESULTS: Twenty‐one trials compared survival after monotherapy with survival after combined androgen blockade (n = 6871 patients). The meta‐analysis found no statistically significant difference in survival at 2 years between patients treated with combined androgen blockade and those treated with monotherapy (20 trials; hazard ratio [HR] = 0.970; 95% confidence interval [95% CI], 0.866–1.087). The authors determined a statistically significant difference in survival at 5 years that favored combined androgen blockade (10 trials; HR = 0.871; 95% CI, 0.805–0.942). For the subgroup of patients with a good prognosis, there was no statistically significant difference in survival. Adverse effects leading to withdrawal from therapy occurred more often with combined androgen blockade. To the authors' knowledge there is little evidence published to date comparing the effects of combined androgen blockade and monotherapy on quality of life, but the single randomized trial that adequately addressed this outcome reported an advantage for monotherapy over combined androgen blockade. CONCLUSIONS: A thorough examination of the usefulness of combined androgen blockade must balance the modest increase in expected survival observed at 5 years against the increased risk of adverse effects and the potential for adversely affecting the patient's overall quality of life. [See editorial on pages 209–10, this issue.] Cancer 2002;95:361–76. © 2002 American Cancer Society. DOI 10.1002/cncr.10647

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.10647

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

See all 259

Metadata

Authors
Samson, D. J., Seidenfeld, J., Schmitt, B., Hasselblad, V., Albertsen, P. C., Bennett, C. L., Wilt, T. J., & Aronson, N.
Venue
Cancer
Publisher
Wiley
Published
2002-07-11
Volume
95
Issue
2
Pages
361-376
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2032649515
Cited by
259
References
37
FWCI
1.89
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Systematic review and meta‐analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. https://app.cochat.ai/papers/10.1002/cncr.10647
The paper
Samson, D. J., Seidenfeld, J., Schmitt, B., Hasselblad, V., Albertsen, P. C., Bennett, C. L., Wilt, T. J., & Aronson, N. (2002). Systematic review and meta‐analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer. https://doi.org/10.1002/cncr.10647

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.